ClinicalTrials.gg
RecruitingNCT06841679Updated Nov 25, 2025

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2/3 interventional study of Utidelone Capsule and Utidelone Capsule in Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
778
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.

02

Conditions studied

  • Gastric or Gastroesophageal Junction Adenocarcinoma

Keywords

  • UTD2
  • GC
  • GEJ
03

In context

Lead sponsor

Beijing Biostar Pharmaceuticals Co., Ltd. is the lead sponsor of 14 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet the following criteria to be eligible for the study:

    1. Sign the form (ICF) to participate with accordance with GCP, ICH and local regulations and are willing to adhere to the study protocol.
    2. Male and female aged ≥ 18 years as of the date of baseline visit.
    3. Participant must have unresectable locally advanced or GC or GEJ and have histologically/pathologic confirmed predominant adenocarcinoma. The documentation of GEJ involvement can include , endoscopy, or imaging.
    4. Phase II Study: No restriction on expression. Phase III study: Participant must have tumor with PD-L1 Combined Positive Score (CPS) \< 1 by immunohistochemical (IHC). IHC results from site are acceptable.
    5. Participant must have at least one per 1.1 criteria.
    6. Participant must not receive previously systemic treatment in the advanced setting. Previously /adjuvant therapy for GC or GEJ with no progression after 6 months from completion is allowed. Palliative radiotherapy is allowed.
    7. (ECOG) performance status of 0 to 1.
    8. Participant with adequate hematological function ( v5.0 Grade ≤ 1) within 1 week before enrollment (based on routine laboratory values at each site) and who have not received recombinant human granulocyte colony-stimulating factor (rhG-CSF) or blood products/erythropoietin (EPO) within 14 days before enrollment.

      • White blood cell count (WBC) ≥ 3.0 × 109/L;
      • (ANC) ≥ 1.5 × 109/L;
      • count (PLT) ≥ 100 × 109/L;
      • (Hb) ≥ 9.0 g/dL.
    9. Participant with adequate liver and renal function (CTCAE v5.0 Grade ≤ 1) within 1 week before enrollment (based on routine laboratory values at each site).

      • Total (TBIL) ≤ 1.5 × (ULN);
      • (ALT) ≤ 3 × ULN (≤ 5 × ULN in patients with hepatic metastases);
      • Aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN in patients with hepatic metastases);
      • (Ccr) ≥ 50 mL/min.
    10. Female Participants of must agree to use highly effective methods during the study and within 6 months after the last dose of the product. Female patients of childbearing potential shall have a negative serum or urine pregnancy test at screening and be willing to have additional pregnancy tests as required throughout the study. Women of non-childbearing potential (WONCBP) must not donate ova from signing informed consent until at least 6 months after the last administration of the investigational product. Please refer to Appendix 1. Males must be surgically sterile (> 6 months since vasectomy with confirmation of no viable sperm), or if engaged in sexual relations (intercourse) with a WOCBP, either his partner must be surgically sterile (eg, hysterectomy, bilateral salpingectomy, bilateral oophorectomy), or an acceptable, highly effective contraceptive method must be used from Screening until 6 months after last IMP administration; or Males with same-sex partners (abstinence from penile-vaginal intercourse) or who are abstinent from heterosexual intercourse are not required to use contraception when this is their preferred and usual lifestyle; or Males must not donate sperm from the first dose of IMP until at least 90 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded from the study for any of the following reasons:

    1. Known -positive tumor (HER2-positive is defined as having an IHC score of 3 +, or IHC2 + and positive HER2 expression by in situ hybridization (ISH) (refer to ASCO/CAP guidelines 2020).
    2. Participants with other over the past 5 years, except for cured skin basal cell carcinoma, in-situ carcinoma of the cervix, or papillary thyroid cancer.
    3. Participants who have received radiotherapy or other drug or investigational therapy within 4 weeks prior to the first dose of investigational product.
    4. Participants who have undergone major surgery (except ) had significant trauma within 4 weeks prior to the first dose of investigational product or required elective surgery during the study.
    5. Participants with pre-existing > Grade 1 peripheral sensory neuropathy ( 5.0).
    6. Participants with known to any components of the investigational product.
    7. Participants who are pregnant (positive pregnancy test) or lactating.
    8. Adverse events due to previous anti-tumor therapy have not recovered to CTCAE v5.0 Grade ≤ 1 (except for alopecia and other toxicities judged by the investigator to have no safety risk).
    9. Participants with esophageal obstruction, pyloric obstruction, intestinal obstruction, or inability to eat on their own after gastrointestinal resection, or other factors that cause difficulty swallowing and inability to take oral drugs.
    10. Participants with symptomatic/uncontrollable central nervous system or meningeal metastases, including but not limited to those with confirmed metastatic disease progression by examination within 2 months after radiotherapy or other local treatment, or who are ineligible for enrollment as judged by the investigator.
    11. Participants with uncontrollable bone metastases, i.e., existing or recent fracture risk, recent need for surgery or local radiotherapy, or other crisis conditions as judged by the investigator.
    12. Participants with uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once monthly or more frequently).
    13. Participants with an active infection and who currently require systematic anti-infective therapy.
    14. Participants with known history of (HIV) infection with an exception that if they have not had an opportunistic infection within the past 12 months, they are eligible.
    15. Participants who are positive or positive (who are HBsAg negative, or HCV antibody negative could be eligible without testing for HBV DNA or HCV RNA).
    16. Participants with a history of severe cardiovascular and cerebrovascular diseases, including but not limited to:

      • Patients with severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention or second/third-degree atrioventricular block; patients with a mean interval (QTcF) > 470 msec obtained from three 12-lead (ECGs) at rest.
      • Patients who have had an acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other Grade ≥ 3 cardio-cerebrovascular events within 3 months before the first dose.
      • Patients with clinically uncontrollable hypertension.
      • Symptomatic Cerebral Infarction
      • Patients with other cardiac disorders that put the patients at a high risk as judged by the investigator.
    17. Participants with uncontrolled diabetes mellitus.
    18. Participants with a mental disorder or poor compliance.
    19. Participants also participate in another interventional clinical study or receive other study treatments (patients who have discontinued other investigational treatments and are only in the follow-up period are allowed to be enrolled in this study).
    20. Participants requiring concomitant use of strong inhibitors or inducers or medications that prolong the QT interval within 14 days prior to the first dose of study treatment and during the study.
    21. Participants with a history of other systemic severe diseases or abnormal laboratory findings that would, in the Investigator's judgment, be inappropriate for this study.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
778 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    UTD2 40 mg/m2/d, po, qd, d1-5, q3w combined with CAPOX/FOLFOX with or without a PD-1 inhibitor ( tislelizumab, or pembrolizumab, or nivolumab )

    Drug: Utidelone Capsule · Drug: Fluoropyrimidine- and Platinum-containing Therapy · Drug: PD-1 inhibitor

  • Experimental
    Cohort 2

    UTD2 50 mg/m2/d, po, qd, d1-5, q3w combined with CAPOX/FOLFOX with or without a PD-1 inhibitor ( tislelizumab, or pembrolizumab, or nivolumab )

    Drug: Utidelone Capsule · Drug: Fluoropyrimidine- and Platinum-containing Therapy · Drug: PD-1 inhibitor

  • Experimental
    Cohort 3

    UTD2 60 mg/m2/d, po, qd, d1-5, q3w combined with CAPOX/FOLFOX with or without a PD-1 inhibitor ( tislelizumab, or pembrolizumab, or nivolumab )

    Drug: Utidelone Capsule · Drug: Fluoropyrimidine- and Platinum-containing Therapy · Drug: PD-1 inhibitor

  • Experimental
    Arm A

    UTD2 po, on d1-5, q3w (dose decided after the phase II) in combination with CAPOX

    Drug: Oxaliplatin · Drug: Utidelone Capsule · Drug: Capecitabine

  • Active comparator
    Arm B

    CAPOX

    Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • UTD2 40 mg/m2/d, po, qd, day 1-5, q3w

  • 50 mg/m2/d, po, qd, day 1-5, q3w

  • 60 mg/m2/d, po, qd, day 1-5, q3w

  • DrugFluoropyrimidine- and Platinum-containing Therapy

    CAPOX: Capecitabine 1700 mg/m2/d, po, bid, d1-14,q3w, Oxaliplatin 130 mg/m2, iv, d1, q3w. After completing 6 times (18 weeks) of oxaliplatin treatment, the investigator may decide whether to continue oxaliplatin treatment for up to 8 times (24 weeks) based on the participant's benefits and safety. FOLFOX: Oxaliplatin 85 mg/m2, iv, d1, q2w. Folinic Acid 400 mg/m2, iv, d1, q2w, 5-FU 400 mg/m2 IV bolus d1 then 5-FU 2400 mg/m2 IV infusion over 46 to 48 hours, q2w. After completing 9 times (18 weeks) of treatment with oxaliplatin combined with folinic acid and 5-FU, the investigator may decide whether to continue FOLFOX treatment for up to 12 times (24 weeks) based on the participant's benefits and safety.

  • 130 mg/m2/d, iv, day1, q3w, oxaliplatin will be given up to 6 cycles

  • UTD2 po, on d1-5, q3w (dose decided after the phase II)

  • Whether to combine a PD-1 inhibitor will depend on the locally approved indications for the PD-1 inhibitor. If the participant's condition meets the locally approved indications for PD-1 inhibitors, the investigator may determine, in accordance with clinical guidelines, that the participant is eligible to receive treatment with UTD2 combined with fluoropyrimidine- and platinum-containing therapy, with or without a PD-1 inhibitor. If a PD-1 inhibitor is administered in combination, tislelizumab (200 mg), or pembrolizumab (200 mg), or nivolumab (360 mg), iv, day1, q3w. Alternatively, the investigator may select the dosage and administration cycle of other locally approved PD-1 inhibitors in accordance with the locally approved package inserts. The PD-1 inhibitor will be given up to 2 years.

  • Capecitabine 1700 mg/m2/d po, bid, d1-14,q3w

  • Capecitabine, 2000 mg/m2/d, po, bid, d1-14, q3w

This study also gives Pembrolizumab, Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of UTD2 and capecitabine in combination with oxaliplatin in Phase II

    dose limiting toxicity (DLT), defined as any toxicity meeting the criteria outlined in the protocol during Cycle 1 in a 21-days cycle

    Time frame: From Day 1 to Day 21

  2. Overall Survival (OS)

    From the first dosing until death (from any cause), follow-up began after the end of treatment

    Time frame: 12 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    Response rate is the proportion of evaluable patients who are evaluated as having a CR or PR.

    Time frame: 12 months

  2. Progression Free Survival (PFS)

    refers to the time from first dosing to the occurrence of tumor progression or death (whichever occurs first)

    Time frame: 12 months

  3. Maximum (or peak) serum concentration (Cmax)

    Cmax of Utidelone Capsule

    Time frame: 12 months

  4. Time to peak drug concentration (Tmax)

    Tmax of Utidelone Capsule

    Time frame: 12 months

  5. the area under the concentration-time curve from dosing (time 0) to time t (AUC0-t)

    the AUC0-t of Utidelone Capsule

    Time frame: 12 months

  6. the area under the concentration-time curve from time zero to infinity (AUCinf)

    the AUC0inf of Utidelone Capsule

    Time frame: 12 months

  7. the time required for plasma concentration of a drug to decrease by 50% (t1/2)

    the t1/2 of Utidelone Capsule

    Time frame: 12 months

  8. Treatment-emergent Adverse Events (TEAE)

    Adverse events (AEs) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event version 5.0 (CTCAE v5.0)

    Time frame: Until 28 days after the last dose of treatment

Other outcomes

  1. Patient reported outcomes (PRO)

    A questionnaire derived from NCI-PRO-CTCAE version 1.0 will be used to assess patient reported safety

    Time frame: 12 months

07

Study locations

6 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Sep 2030, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 24, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2030
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06841679
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Feb 24, 2025
Start date
Aug 28, 2025
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2030 (estimated)
Last update
Nov 25, 2025

Study contacts

Rongguo Qiu
Contact
Rqiu2001@yahoo.com
010-56315388

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desoxyepothilone B · Oxaliplatin · Capecitabine

Start the discussion